Although several studies demonstrate that PBSO decreased the risk of both breast and ovarian cancers in BRCA1/2 mutation carriers[85-94], these studies were nevertheless heterogeneous and used different designs: whilst some were retrospective case control studies, others used a prospective cohort design. This evidence concerns the gene BRCA1 and ovarian carcinoma.